A COVID-19 risk score helped steer outreach efforts to people who weren’t getting vaccinated by the pharmacy chain earlier in the pandemic.
An outreach effort by Walgreens based on a homegrown COVID-19 risk index resulted in a greater number of people from disadvantaged situations receiving the first dose of the Moderna COVID-19 vaccine, according to research presented at the Academy of Managed Care Pharmacy’s annual meeting, AMCP 2022, this week in Chicago.
Roberts
“At the beginning of the epidemic we were actually doing a fairly poor job of targeting the most vulnerable population. We recognized that very quickly,” said Erin Roberts, M.P.H., a senior healthcare analyst at Walgreens who first author of the team reporting the results at AMCP 2022.
Roberts said that she, with the help of others, developed a COVID-19 risk score based on medications people were taking (information available to Walgreens), where they lived, their race and ethnicity, and other factors. They used those risk scores to organize outreach efforts that prioritized people at the greatest risk. The outreach efforts include phone calls, in-person discussions with pharmacists and some special efforts, such as sending “vaccination vans” to churches in areas with low vaccination rates,
A chart in the poster that Roberts presented at the meeting showed the percentage of people from counties with high social vulnerability index levels who received the Moderna vaccine at a Walgreens lagged behind those from counties with lower social vulnerability indexes at the beginning of the pandemic. According to that chart, in June 2021, the relationship reversed, and Walgreens vaccinees from counties with a higher social vulnerability exceeded those from counties with lower indexes.
Overall, from Dec. 18, 2020, through Dec. 31, 2020, the 17.1% (823,473 of 4,812,847) of the people who received at least one dose of the Moderna vaccine at a Walgreens or one of the company’s outreach sites were from counties with a high social vulnerability index. Those from counties with a low social vulnerability index constituted 19.93% (959,099 of 4,812, 847).
Roberts’ poster shows that a larger proportion of the people that Walgreens vaccinated with the Moderna vaccine were Hispanic/Latino than those in the U.S. population (18.5% vs. 17.2%) but a smaller portion of the drugstore chains vaccinees were Black (11.8% vs. 12.4%).
Roberts also reported that 36% of the Walgreens patients in rural areas received at least one dose of the Moderna vaccine.
Roberts said she is working on paper that will report research identifying which types of outreach efforts are more effective at getting people vaccinated. She is also examining the factors affecting the uptake of the second of the initial two-dose series of the Moderna vaccine and the booster.
Walgreens pharmacists also vaccinate people with the Pfizer vaccine, so this research, sponsored by Moderna, paints an incomplete picture of Walgreens’ vaccination efforts.
Roberts said the overall number of people vaccinated by Walgreens and the importance of having pharmacists administer the COVID-19 vaccines should be one of the takeaways from her research.
“Walgreens alone and just for the Moderna vaccine, vaccinated almost 5 million patients. If pharmacists were not allowed to vaccinate, we don’t necessarily know that these patients would have had access to vaccine, especially these patients who are in rural areas that are highly socially vulnerable that may have a distrust of their doctor or no doctor at all.”
Innovations in Pharmacy and Its Impact on Managed Care
March 29th 2023Managing Directors of L.E.K. Consulting, Joe Johnson, Todd Clark and Brendan Mitchell introduce the innovations happening in pharmacy, more specifically disruptive innovations, and how they affect managed care. The team explained some of the innovations to be on the lookout for in the future, also.
Read More
Tis Full and Very, Very Expensive: the 2023 Specialty Drug Pipeline | AMCP 2023
March 24th 2023Specialty drugs are expected to comprise 80% of the FDA approvals this year. Among them are gene therapies for hemophilia A and Duchenne muscular dystrophy priced at between $2 million and $3 million.
Read More
Some Things Old, Many Things New When It Comes to Payer PDT Review | AMCP 2023
March 24th 2023Coverage decisions about prescription digital therapeutics may take payers out of their comfort zones and require new processes and subject matter experts, according to members of a panel at the AMCP annual meeting. But P&T committees are likely to still be central to the process.
Read More
For Weight Loss, Off-Label GLP-1s Are Increasingly the Chosen Ones | AMCP 2023
March 24th 2023They are the trendy way to lose weight and payers have been noticing an increase in GLP-1 claims. An analysis of the pharmacy and healthcare claims of a small commercial health plan in Texas documents the growth in the off-label usage of the GLP-1s, such as Ozempic, for weight loss.
Read More
2 Clarke Drive
Cranbury, NJ 08512